Disappointment for Diamyd's gene therapy painkiller
This article was originally published in Scrip
Executive Summary
Diamyd Medical's NP2 Enkephalin, a gene therapy for pain, failed to meet its primary objective of reducing pain in patients with severe intractable cancer pain in a Phase II study, sending the Swedish firm's share price down by over 40%.